Intellia Therapeutics (NTLA) Stock Forecast, Price & News

Intellia Therapeutics (NASDAQ:NTLA) Frequently Asked Questions

Is Intellia Therapeutics a buy right now?

21 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Intellia Therapeutics in the last year. There are currently 2 hold ratings and 19 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Intellia Therapeutics stock.
View analyst ratings for Intellia Therapeutics or view top-rated stocks.

When is Intellia Therapeutics' next earnings date?

Intellia Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Intellia Therapeutics.

How were Intellia Therapeutics' earnings last quarter?

Intellia Therapeutics, Inc. (NASDAQ:NTLA) announced its quarterly earnings results on Thursday, May, 5th. The company reported ($1.96) EPS for the quarter, missing analysts' consensus estimates of ($1.11) by $0.85. The company had revenue of $11.30 million for the quarter, compared to the consensus estimate of $8.57 million. Intellia Therapeutics had a negative net margin of 973.48% and a negative trailing twelve-month return on equity of 41.00%. The firm's quarterly revenue was up 73.8% on a year-over-year basis. During the same period in the prior year, the company earned ($0.69) earnings per share.
View Intellia Therapeutics' earnings history.

What price target have analysts set for NTLA?

21 brokers have issued twelve-month price objectives for Intellia Therapeutics' stock. Their forecasts range from $83.00 to $252.00. On average, they expect Intellia Therapeutics' stock price to reach $143.50 in the next year. This suggests a possible upside of 200.6% from the stock's current price.
View analysts' price targets for Intellia Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Intellia Therapeutics' key executives?

Intellia Therapeutics' management team includes the following people:

• Dr. John M. Leonard M.D., Pres, CEO & Director (Age 65, Pay $912.79k) (LinkedIn Profile)
• Mr. Glenn G. Goddard CPA, Exec. VP, CFO & Treasurer (Age 51, Pay $562.45k) (LinkedIn Profile)
• Dr. Laura Sepp-Lorenzino, Exec. VP & Chief Scientific Officer (Age 61, Pay $609.38k) (LinkedIn Profile)
• Dr. David Lebwohl M.D., Exec. VP & Chief Medical Officer (LinkedIn Profile)
• Mr. Nessan Bermingham Ph.D., Founder & Member of Scientific Advisor Board (Age 49)
• Dr. Rachel E. Haurwitz Ph.D., Co-Founder (Age 36)
• Dr. Andrew May, Founder and Member of Scientific Advisor Board
• Dr. Jennifer A. Doudna Ph.D., Founder & Member of Scientific Advisor Board (Age 58)
• Dr. Derrick J. Rossi, Founder & Member of Scientific Advisor Board
• Dr. Rodolphe Barrangou M.B.A., Ph.D., Founder & Member of Scientific Advisor Board

What is John Leonard, M.D.'s approval rating as Intellia Therapeutics' CEO?

12 employees have rated Intellia Therapeutics CEO John Leonard, M.D. on Glassdoor.com. John Leonard, M.D. has an approval rating of 73% among Intellia Therapeutics' employees.

Who are some of Intellia Therapeutics' key competitors?

Some companies that are related to Intellia Therapeutics include Ipsen (IPSEY), Lantheus (LNTH), Quidel (QDEL), Ortho Clinical Diagnostics (OCDX), Neogen (NEOG), Myriad Genetics (MYGN), Celldex Therapeutics (CLDX), Meridian Bioscience (VIVO), Heska (HSKA), Alpha Teknova (TKNO), VolitionRx (VNRX), VolitionRx (VNRX), Nymox Pharmaceutical (NYMX), OncoCyte (OCX) and MyMD Pharmaceuticals (MYMD).
View all of NTLA's competitors.

What other stocks do shareholders of Intellia Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intellia Therapeutics investors own include Editas Medicine (EDIT), CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Alibaba Group (BABA), Square (SQ), Micron Technology (MU), Advanced Micro Devices (AMD), Intel (INTC), Invitae (NVTA) and Cisco Systems (CSCO).

When did Intellia Therapeutics IPO?

(NTLA) raised $85 million in an initial public offering on Friday, May 6th 2016. The company issued 5,000,000 shares at $16.00-$18.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Intellia Therapeutics' stock symbol?

Intellia Therapeutics trades on the NASDAQ under the ticker symbol "NTLA."

Who are Intellia Therapeutics' major shareholders?

Intellia Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include ARK Investment Management LLC (12.03%), Vanguard Group Inc. (8.43%), BlackRock Inc. (7.38%), Sumitomo Mitsui Trust Holdings Inc. (3.85%), Nikko Asset Management Americas Inc. (3.85%) and Viking Global Investors LP (3.25%). Company insiders that own Intellia Therapeutics stock include Andrew Schiermeier, Caroline Dorsa, David Lebwohl, Glenn Goddard, Jean Francois Formela, John F Crowley, John M Leonard, John M Leonard, Jose E Rivera, Jose E Rivera, Laura Sepp-Lorenzino and Perry A Karsen.
View institutional ownership trends for Intellia Therapeutics.

Which major investors are selling Intellia Therapeutics stock?

NTLA stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Lord Abbett & CO. LLC, Goldman Sachs Group Inc., Dimensional Fund Advisors LP, Invesco Ltd., Chevy Chase Trust Holdings Inc., Prudential Financial Inc., and Vanguard Group Inc.. Company insiders that have sold Intellia Therapeutics company stock in the last year include David Lebwohl, Glenn Goddard, Jean Francois Formela, John F Crowley, John M Leonard, and Laura Sepp-Lorenzino.
View insider buying and selling activity for Intellia Therapeutics or view top insider-selling stocks.

Which major investors are buying Intellia Therapeutics stock?

NTLA stock was purchased by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Viking Global Investors LP, State Street Corp, Citigroup Inc., Polar Capital Holdings Plc, Frazier Life Sciences Management L.P., Wellington Management Group LLP, and Nikko Asset Management Americas Inc..
View insider buying and selling activity for Intellia Therapeutics or or view top insider-buying stocks.

How do I buy shares of Intellia Therapeutics?

Shares of NTLA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Intellia Therapeutics' stock price today?

One share of NTLA stock can currently be purchased for approximately $47.74.

How much money does Intellia Therapeutics make?

Intellia Therapeutics has a market capitalization of $3.62 billion and generates $33.05 million in revenue each year. The company earns $-267.89 million in net income (profit) each year or ($5.030010) on an earnings per share basis.

How many employees does Intellia Therapeutics have?

Intellia Therapeutics employs 485 workers across the globe.

What is Intellia Therapeutics' official website?

The official website for Intellia Therapeutics is www.intelliatx.com.

How can I contact Intellia Therapeutics?

Intellia Therapeutics' mailing address is 40 Erie Street Suite 130, Cambridge MA, 02139. The company can be reached via phone at (857) 285-6200 or via email at [email protected].